Enliven Therapeutics doubles authorized common shares to 200M, annual meeting votes pass

Enliven Therapeutics, Inc.

Stockholders approved amendment increasing authorized common shares from 100M to 200M; effective June 9, 2026.
Elected Class III directors Richard Fair and Lori Kunkel with 99.7% and 64.7% of votes cast, respectively.
Ratified Deloitte & Touche as independent auditor for FY2026 with overwhelming support (56.1M for).
Advisory say-on-pay approved (47.6M for, 89.5% of votes cast); advisory vote on frequency set to every one year.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Enliven Therapeutics, Inc.: Increased authorized shares of common stock from 100,000,000 to 200,000,000 (effective 2026-06-09).

Change: charter amendment
Effective: 2026-06-09

Exact text from the filing

On June 9, 2026, following stockholder approval, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000, which amendment was effective as of the date of filing.

View on SEC.gov

255 governance changes filed in the last 30 days. Browse all governance changes →

Enliven Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-264085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.